PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-31.82%
Both yoy net incomes decline, with VET at -20.86%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
1.87%
D&A growth well above VET's 1.57%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
176.39%
Well above VET's 159.97% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
No Data
No Data available this quarter, please select a different quarter.
245.16%
Well above VET's 74.47% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
245.16%
Growth of 245.16% while VET is zero at 0.00%. Bruce Berkowitz would see a difference in minor WC usage that might affect short-term cash flow if large.
-843.75%
Negative yoy while VET is 28.84%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
38.84%
Operating cash flow growth at 50-75% of VET's 61.32%. Martin Whitman would worry about lagging operational liquidity vs. competitor.
-5.63%
Both yoy lines negative, with VET at -58.30%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
103.70%
Acquisition growth of 103.70% while VET is zero at 0.00%. Bruce Berkowitz sees a mild outflow that must deliver synergy to justify the difference.
-266.67%
Negative yoy purchasing while VET stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
5.63%
We have some liquidation growth while VET is negative at -100.00%. John Neff notes a short-term liquidity advantage if competitor is holding or restricted.
-2.44%
We reduce yoy other investing while VET is 154.28%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-4.25%
We reduce yoy invests while VET stands at 10.59%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
-40.24%
We cut debt repayment yoy while VET is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.